|
Oct 8
|
Scholar Rock’s SMA Treatment Trials Show Promising Results
|
|
Oct 8
|
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says
|
|
Oct 8
|
Scholar Rock stocks skyrocket after SMA drug scores at Phase III
|
|
Oct 7
|
Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy
|
|
Oct 7
|
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
|
Oct 7
|
Scholar Rock Shares Quadruple On Positive Drug-Study Results
|
|
Oct 7
|
Top Midday Gainers
|
|
Oct 7
|
Scholar Rock stock surges on positive spinal muscular atrophy treatment data
|
|
Oct 7
|
Scholar Rock Stock Quadruples on Positive Trial Data
|
|
Oct 7
|
Update: Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint
|
|
Oct 7
|
Scholar Rock scores with ‘surprise’ success in SMA drug study
|
|
Oct 7
|
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
|
|
Sep 27
|
Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now
|
|
Sep 10
|
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
|
|
Jul 23
|
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
|
|
Jun 24
|
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
|
|
Jun 3
|
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
|
|
May 22
|
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
|
|
May 14
|
Scholar Rock to Host Investor Day on May 22, 2024
|
|
May 7
|
Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis
|